Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialMarco Colleoni, Joanna Vermeij, Stefan Aebi et al.|The Lancet Oncology|2017Cited by 122
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast CancerSaverio Cinieri, Uğur Çoşkun, Arlene Chan et al.|Clinical Breast Cancer|2016Cited by 12